Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
Webinars will be available for unlimited on-demand viewing after live event.
A-TEEM spectroscopy is an emerging technique with huge potential for QC laboratories in the pharmaceutical and biopharmaceutical industries. We present a set of tools for A-TEEM spectroscopy...
Join this year's poster presenters in the Poster Hall during the Poster Networking Hour, Wednesday, September 6th, from 1:00 –2:00 PM PDT , to chat live about their posters and lat...
Histology laboratorians in the research world move fast, but those who perform cryosectioning know that these particular tissues require lighting speed and precision. Cryosectioning is the a...
Join us for an illuminating webinar as we delve into the realm of open automation with Inpeco, the global leader in Total Laboratory Automation. Discover how their groundbreaking s...
Loading Comments...
Please update your information
Certificate of Attendance
Thank you for choosing Labroots. Please note that a Certificate of Attendance does NOT count towards Continuing Education Credits.